SN
SNWV.US SANUWAVE Health, Inc. Common Stock
- Market cap
- USD 14.6M
- P/E
- -
- P/B
- 5.49x
- ROE
- -165.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SNWV.US undervalued?
Graham numberThe Graham number of SANUWAVE Health, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SANUWAVE Health, Inc. Common Stock fundamental analysis
No fundamental analysis for SANUWAVE Health, Inc. Common Stock yet.
SANUWAVE Health, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SANUWAVE Health, Inc. Common Stock
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a…
Full company profileSANUWAVE Health, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SANUWAVE Health, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.38M | 739K | 1.85M | 1.03M | 4.06M | 13.0M | 16.7M | 20.4M | 32.6M | 44.1M | 37.2M |
| Gross Profit | 811K | 497K | 1.16M | 490K | 2.90M | 8.02M | 12.4M | 14.4M | 24.6M | 34.0M | 28.3M |
| Operating Income | -3.32M | -3.82M | -7.18M | -8.79M | -18.0M | -14.1M | -8.95M | -540K | 5.42M | 4.95M | -3.30M |
| EBITDA | -2.99M | -4.37M | -7.11M | -8.52M | -27.4M | -18.9M | 4.79M | -9.15M | -16.6M | 19.4M | -1.59M |
| Net Income | -6.44M | -5.54M | -11.6M | -10.4M | -30.9M | -27.3M | -10.3M | -25.8M | -31.4M | 11.8M | -4.72M |
| EPS | -0.06 | -0.04 | -0.08 | -0.05 | -0.07 | -0.05 | -0.02 | -0.03 | -7.03 | 1.30 | -0.55 |
| Balance Sheet | |||||||||||
| Total Assets | 1.00M | 1.28M | 1.18M | 3.38M | 23.0M | 18.6M | 19.9M | 22.4M | 30.1M | 37.3M | 32.5M |
| Total Liabilities | 7.92M | 11.2M | 16.5M | 13.4M | 36.7M | 57.6M | 60.9M | 65.6M | 42.8M | 35.7M | 29.7M |
| Shareholders' Equity | -6.91M | -9.88M | -15.4M | -10.1M | -13.7M | -39.0M | -41.0M | -43.2M | -12.7M | 1.62M | 2.85M |
| Cash & Short-term Investments | 134K | 730K | 365K | 1.76M | 2.44M | 619K | 1.15M | 1.80M | 10.2M | 12.0M | 6.57M |
| Total Debt | 5.52M | 6.05M | 10.8M | 6.92M | - | 26.2M | 41.1M | 31.9M | 25.5M | 23.0M | 18.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.20M | -1.53M | -3.62M | -6.41M | -12.7M | -6.41M | -17.2M | -4.54M | 2.46M | 3.88M | -38.7K |
| Capital Expenditure | 10.4K | 42.9K | 42.9K | 53.9K | 53.0K | 529K | 1.02M | 0.00 | 490K | 1.94M | 751K |
| Free Cash Flow | -3.21M | -1.53M | -3.66M | -6.46M | -12.8M | -6.94M | -16.1M | -4.54M | 1.97M | 1.93M | -789K |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | - | - | - | 729.6% | -165.5% |
| ROA | -640.8% | -433.1% | -987.6% | -308.4% | -134.3% | -146.4% | -51.8% | -115.1% | -104.2% | 31.6% | -14.5% |
| Net Profit Margin | -467.9% | -749.9% | -628.7% | -1,013.9% | -762.5% | -209.5% | -61.5% | -126.5% | -96.1% | 26.8% | -12.7% |
| Debt to Equity | - | - | - | - | - | - | - | - | - | 14.19x | 6.50x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SANUWAVE Health, Inc. Common Stock dividends
SANUWAVE Health, Inc. Common Stock has not paid dividends in the last 9 fiscal years.
Last stock split: 1:375 on Oct 18, 2024.
Who owns SANUWAVE Health, Inc. Common Stock
- Insiders 1.31%
- Institutions 30.37%
- Public & others 68.32%
- Shares outstanding 8.60M
- Free float 6.64M
Top funds holding SNWV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 265K | 3.08% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 39.8K | 0.46% | -0.38% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 25.1K | 0.29% | +1.92% | Oct 2026 |
| iShares Micro-Cap ETF | 23.6K | 0.27% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 13.6K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 10.6K | 0.12% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 9.27K | 0.11% | +181.11% | Jun 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 4.23K | 0.05% | 0.00% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 3.62K | 0.04% | -36.01% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 3.59K | 0.04% | 0.00% | Aug 2026 |
| Fidelity ZERO Total Market Index | 3.56K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 3.24K | 0.04% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.75K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Flex Small Cap Index | 1.06K | 0.01% | -27.24% | Aug 2026 |
| Victory Extended Market Index | 929.00 | 0.01% | -1.17% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 787.00 | 0.01% | -11.27% | Sep 2026 |
| Fidelity VIP Extended Mkt Indx Initial | 501.00 | 0.01% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 268.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding SNWV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Solas Capital Management LLC | 611K | 7.10% | +112.50% | Jun 2026 |
| Awm Investment Company Inc | 455K | 5.28% | 0.00% | Jun 2026 |
| Praetorian PR LLC | 395K | 4.59% | +12.86% | Jun 2026 |
| Vanguard Capital Management, LLC | 353K | 4.10% | +1.11% | Jun 2026 |
| Opaleye Management Inc | 306K | 3.56% | -68.80% | Jun 2026 |
| UBS Group AG | 257K | 2.99% | +22.13% | Jun 2026 |
| BlackRock Inc | 160K | 1.86% | -66.80% | Jun 2026 |
| Geode Capital Management, LLC | 86.1K | 1.00% | -49.88% | Jun 2026 |
| Citadel Advisors Llc | 59.5K | 0.69% | +228.62% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 43.1K | 0.50% | -12.55% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 42.1K | 0.49% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 40.4K | 0.47% | +4.99% | Jun 2026 |
| JPMorgan Chase & Co | 39.7K | 0.46% | +1,202.40% | Jun 2026 |
| Stonebridge Wealth Management, LLC | 38.4K | 0.45% | +3.36% | Jun 2026 |
| Luxor Capital Group, LP | 37.2K | 0.43% | 0.00% | Jun 2026 |
| State Street Corp | 32.3K | 0.38% | -76.96% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 31.6K | 0.37% | +445.81% | Jun 2026 |
| Jane Street Group LLC | 23.8K | 0.28% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 22.9K | 0.27% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 21.8K | 0.25% | +48.72% | Jun 2026 |
SANUWAVE Health, Inc. Common Stock company profile
- Company name
- SANUWAVE Health, Inc. Common Stock
- Ticker
- SNWV.US
- Exchange
- USA Stocks
- Listed since
- Mar 10, 2015
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 55
- Fiscal year end
- December
- Address
- 9600 W. 76th Street, Eden Prairie, MN, United States, 55344
- Phone
- 952 656 1029
- Website
- sanuwave.com
About SANUWAVE Health, Inc. Common Stock
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds. The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
SANUWAVE Health, Inc. Common Stock management
8- Mr. Morgan C. FrankCEO & Chairman · born 1972
- Mr. Daniel CoyleChief Operating Officer · born 1991
- Mr. Timothy WernExecutive Vice President of Sales - U.S. Wound · born 1968
- Mr. Peter SorensenCFO & Secretary · born 1993
- Dr. Christopher Cook Ph.D.Chief Technology Officer
- Mr. Peter StegagnoChief Regulatory Officer · born 1960
- Mr. Dustin LibbyExecutive Vice President of Commercial Operations
- Mr. Mitch LewandowskiEVP of Quality & Regulatory Affairs